Findings
What does this study add?
- AHCL therapy improved mean HbA1c from 7.5% to 7.0%.
- Almost twice as many patients achieved an HbA1c≤7.0% with AHCL therapy vs. baseline.
- More participants achieved a TIR70-180 ≥70%.
- This further increased for all groups at the basal target set point of 100 mg/dL.
- There were no events of diabetic ketoacidosis, severe hypoglycemia during the study phase, serious or unanticipated adverse device effects.